Daniel J. Lippis is CVP & TAVR at Edwards Lifesciences Corp (EW). They have made 3 open-market trades across 1 company since 2024, most recently 2026-10-08.
CIK 0002004380
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| EW | 40,033 | $3.5M |
Shares reported on the most recent Form 4, priced at the 2026-10-08 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EW | SELL · 10b5-1 | 2026-10-08 | 2026-10-08 | $85.65 | $53K | — | — | — |
| EW | SELL · 10b5-1 | 2026-09-11 | 2026-09-11 | $87.51 | $54K | +1.4% | +1.0% | — |
| EW | SELL · 10b5-1 | 2026-08-11 | 2026-08-11 | $92.03 | $57K | -2.8% | -6.1% | — |
| EW | SELL · 10b5-1 | 2026-07-10 | 2026-07-10 | $91.70 | $57K | -8.1% | +0.2% | -8.2% |
| EW | SELL · 10b5-1 | 2026-06-30 | 2026-06-30 | $91.40 | $57K | +1.0% | -4.4% | -4.5% |
| EW | SELL · 10b5-1 | 2026-05-18 | 2026-05-18 | $81.14 | $50K | +4.8% | +5.0% | +10.0% |
| EW | SELL · 10b5-1 | 2026-05-01 | 2026-05-04 | $83.49 | $170K | -2.6% | +2.9% | +6.3% |
| EW | SELL · 10b5-1 | 2026-04-06 | 2026-04-06 | $80.98 | $83K | -1.9% | +3.2% | +18.0% |
| EW | SELL | 2026-03-11 | 2026-03-11 | $85.38 | $87K | -3.5% | -8.3% | +3.0% |
| EW | SELL | 2026-01-09 | 2026-01-09 | $85.70 | $87K | -1.8% | -10.7% | -8.0% |
| EW | SELL · 10b5-1 | 2025-12-12 | 2025-12-12 | $84.03 | $171K | +3.3% | -0.7% | +1.2% |
| EW | SELL · 10b5-1 | 2025-11-10 | 2025-11-10 | $82.55 | $84K | -0.4% | -0.6% | -9.0% |
| EW | SELL | 2025-07-28 | 2025-07-28 | $79.46 | $654K | -2.0% | +1.8% | +1.7% |
| EW | SELL · 10b5-1 | 2025-05-09 | 2025-05-09 | $74.42 | $25K | +2.3% | +2.6% | +4.7% |
| EW | SELL · 10b5-1 | 2025-04-08 | 2025-04-08 | $70.61 | $21K | +3.9% | +12.1% | +15.2% |
| EW | SELL · 10b5-1 | 2025-03-10 | 2025-03-10 | $69.48 | $28K | +4.0% | +2.4% | +11.9% |
| EW | SELL · 10b5-1 | 2025-02-13 | 2025-02-13 | $76.34 | $38K | -5.6% | -7.3% | +0.7% |
| EW | SELL · 10b5-1 | 2025-01-16 | 2025-01-16 | $68.76 | $34K | +1.7% | +8.2% | +1.8% |
| EW | SELL · 10b5-1 | 2024-12-16 | 2024-12-16 | $74.08 | $185K | +2.9% | -4.4% | -3.9% |
| EW | SELL · 10b5-1 | 2024-07-11 | 2024-07-11 | $94.18 | $47K | -6.2% | -29.4% | -26.7% |
| EW | SELL · 10b5-1 | 2024-06-20 | 2024-06-20 | $90.00 | $48K | +1.8% | -1.8% | -24.6% |
| EW | SELL · 10b5-1 | 2024-05-07 | 2024-05-09 | $85.60 | $147K | +3.1% | -1.7% | -30.3% |
| EW | SELL · 10b5-1 | 2024-04-09 | 2024-04-09 | $92.34 | $158K | -6.3% | -4.7% | +0.1% |
| EW | SELL · 10b5-1 | 2024-03-07 | 2024-03-07 | $90.98 | $312K | +1.0% | -1.1% | -6.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.